When combined with anti-PD-1 therapy, enoblituzumab further amplifies IFN-γ secretion and enhances its production in both NK and CD8+ T cells [49], supporting the rationale for their combined use to improve anti-tumor immunity. Here, CD8A is linked to neoplasm.